IMWP Monographs on Favipiravir and on Favipiravir tablets

Overview

(The pharmacopoeial alert system, established at the 9th IMWP meeting in Da Nang, Vietnam, was convened for the first time in response to the COVID-19 pandemic. The main outcomes of the meetings can be found in the report of the 12th IMWP ( see here). They include the development of the IMWP monographs on Favipiravir and on Favipiravir tablets to assist those involved in the fight against falsified and substandard products (such as official control laboratories). IMWP monographs are not legally binding or intended to become official standards (even if they could serve as a basis). They can be used on a voluntary basis. The development of these monographs does not imply or confer any demonstrated effectiveness of favipiravir in the treatment of COVID-19, nor does it recommend its therapeutic use.

The IMWP monographs on Favipiravir and on Favipiravir tablets were developed by the Japanese Pharmacopoeia with support from other pharmacopoeias.